Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New COVID vaccine trial targets healthy Middle-Aged adults

NCT ID NCT07279766

Vaccine Sponsor: Tor Biering-Sørensen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large study tests whether an updated Moderna COVID-19 vaccine can prevent severe COVID-19 in adults aged 50 to 64 who have no health conditions that raise their risk. About 285,000 participants will be randomly assigned to get the vaccine or not. The main goal is to see if the vaccine reduces doctor visits or hospital stays for COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Moderna COVID-19 vaccine (updated variant formulation)
What this could lead to
If successful, this could show that healthy adults aged 50-64 benefit from an updated COVID-19 vaccine to prevent severe illness.
What could go wrong
This trial only includes people without risk factors, so results may not apply to everyone. It is also pragmatic, meaning real-world factors could affect outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 285,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 64 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 50-64 years * Informed consent form has been signed and dated Exclusion Criteria: * Medical conditions that increase the risk of severe COVID-19, which will be assessed through self-reporting. These medical conditions include: 1. Asthma 2. Cancer (excluding non-melanoma skin cancer) 3. Cardiomyopathies 4. Cerebrovascular disease 5. Chronic kidney disease 6. Chronic lung disease 7. Cystic Fibrosis 8. Dementia 9. Diabetes 10. Down syndrome 11. Heart failure 12. Human Immunodeficiency Virus 13. Immunosuppressive therapy 14. Ischemic heart disease 15. Liver disease 16. Neurological/neuromuscular disease 17. Psychiatric disease (psychotic, schizophrenic, schizotypal, depressive, and bipolar (affective) disorders). 18. Severe obesity (body mass index \>35 kg/m2) 19. Severe substance abuse 20. Short bowel syndrome 21. Solid organ transplant or hematological transplant * Apart from these, there are no specific exclusion criteria for this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory system disorder COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19

Contacts and locations

Locations

  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

    Hellerup, 2900, Denmark

  • Danske Lægers Vaccinations Service

    Søborg, 2860, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.